CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share (CBIO)

Q: What does CUSIP G2545C104 represent in this 13F holders report?

CUSIP G2545C104 is the security identifier for CBIO - CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held CBIO - CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share in Q4 2025?

54 institutional investors reported CBIO - CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: G2545C104

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Ordinary Shares, $0.001 par value per share
Shares outstanding: 27,553,444
Total 13F shares: 23,741,798
Share change: +12,046,496
Total reported value: $281,443,423
Price per share: $11.86
Number of holders: 54
Value change: +$142,716,069
Number of buys: 35
Number of sells: 15

Security key

G2545C104

Report period

Q4 2025

Institutions

Top holders

Full security history Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP G2545C104

Newer quarter: Q1 2026 Previous quarter: Q3 2025

Recent filing periods:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of CBIO - CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Fairmount Funds Management LLC	13D/G 3/4/5 13F	Director, 10%+ Owner · Company	19%	5,643,482	$73,252,396	+$32,700,021	04 Dec 2025	13D/G 3/4/5 13F
FMR LLC	13D/G 13F	Company	15%	4,133,514	$49,932,849	$0	31 Dec 2025	13D/G 13F
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	9.5%	2,666,064	$29,460,007	$0	31 Dec 2025	13D/G
ForGrowth III PA B.V.	13D/G	—	6.1%	1,677,852	$21,778,519	$0	08 Dec 2025	13D/G
1Globe Capital LLC	13D/G	—	10%	1,425,432	$20,839,816	+$7,729,886	07 Oct 2025	13D/G
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	1,387,863	$18,736,150	$0	30 Jun 2025	13D/G
Vestal Point Capital, LP	13D/G	—	5.4%	1,500,000	$16,575,000	$0	31 Dec 2025	13D/G
VR Adviser, LLC	13F	Company	5%	1,387,864	$16,501,703	—	30 Sep 2025	13F
BVF INC/IL	13F	Company	5%	1,387,863	$16,501,691	—	30 Sep 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	2.5%	679,824	$8,083,107	—	30 Sep 2025	13F
VANGUARD GROUP INC	13F	Company	2.4%	657,900	$7,822,431	—	30 Sep 2025	13F
Logos Global Management LP	13D/G 13F	Company	4.1%	575,000	$7,762,500	$0	30 Jun 2025	13D/G 13F
PERCEPTIVE ADVISORS LLC	13F	Company	1.6%	453,686	$5,394,327	—	30 Sep 2025	13F
Boxer Capital Management, LLC	13F	Company	1.6%	453,686	$5,394,326	—	30 Sep 2025	13F
Deep Track Capital, LP	13F	Company	1.6%	453,686	$5,394,326	—	30 Sep 2025	13F
Commodore Capital LP	13F	Company	1.6%	450,829	$5,360,357	—	30 Sep 2025	13F
Scott D. Sandell	3/4/5	10%+ Owner	— class O/S missing	2,237,196	$5,279,783	—	25 Jan 2023	3/4/5
Joshua T. Brumm	3/4/5	Chief Executive Officer, Director	— mixed-class rows	503,984 mixed-class rows	$4,878,636	—	15 Dec 2025	3/4/5
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.4%	383,595	$4,561,000	—	30 Sep 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	1.1%	302,457	$3,596,214	—	30 Sep 2025	13F
Frazier Life Sciences Management, L.P.	13F	Company	0.99%	272,951	$3,245,387	—	30 Sep 2025	13F
Jonathan McNeill	3/4/5	President and COO	— mixed-class rows	237,736 mixed-class rows	$2,408,381	—	15 Dec 2025	3/4/5
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.73%	200,005	$2,378,059	—	30 Sep 2025	13F
Soleus Capital Management, L.P.	13F	Company	0.73%	200,000	$2,378,000	—	30 Sep 2025	13F
Siren, L.L.C.	3/4/5	10%+ Owner	— class O/S missing	8,589,064	$2,294,139	—	25 Jul 2024	3/4/5
Rachel K. King	3/4/5	Director	— mixed-class rows	555,194 mixed-class rows	$1,545,582	—	01 May 2024	3/4/5
BlackRock, Inc.	13F	Company	0.4%	109,115	$1,297,377	—	30 Sep 2025	13F
Jefferies Financial Group Inc.	13F	Company	0.37%	102,714	$1,221,269	—	30 Sep 2025	13F
Invus Public Equities, L.P.	3/4/5	10%+ Owner	— class O/S missing	6,317,565	$1,211,077	—	07 Aug 2024	3/4/5
Christopher Grant Doughty	3/4/5	Chief Business Officer	— mixed-class rows	121,049 mixed-class rows	$937,885	—	15 Dec 2025	3/4/5
Blackstone Inc.	13F	Company	0.27%	75,614	$899,050	—	30 Sep 2025	13F
John L. Magnani	3/4/5	SVP of Research, CSO	— class O/S missing	370,923	$875,378	—	11 Nov 2022	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.25%	69,134	$822,016	—	30 Sep 2025	13F
MARSHALL WACE, LLP	13F	Company	0.16%	43,694	$519,522	—	30 Sep 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.13%	36,975	$439,633	—	30 Sep 2025	13F
Chinmaya Rath	3/4/5	SVP and Chief Business Officer	— mixed-class rows	411,178 mixed-class rows	$380,380	—	12 Jan 2024	3/4/5
Jan Pinkas	3/4/5	Chief Scientific Officer	— mixed-class rows	92,532 mixed-class rows	$339,405	—	15 Dec 2025	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.1%	28,318	$336,701	—	30 Sep 2025	13F
Bruce S. Johnson	3/4/5	SVP & Chief Commercial Officer	— mixed-class rows	388,980 mixed-class rows	$327,993	—	12 Jan 2024	3/4/5
Ellie Eunkyung Im	3/4/5	Chief Medical Officer	— mixed-class rows	86,488 mixed-class rows	$321,173	—	15 Dec 2025	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.1%	26,900	$319,841	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.09%	25,593	$304,301	—	30 Sep 2025	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.09%	24,923	$296,334	—	30 Sep 2025	13F
Daniel M. Junius	3/4/5	Director	— mixed-class rows	138,459 mixed-class rows	$295,377	—	01 May 2024	3/4/5
Richard William Scalzo	3/4/5	Chief Financial Officer	— mixed-class rows	77,110 mixed-class rows	$292,883	—	15 Dec 2025	3/4/5
Barbara Harlin Bispham	3/4/5	General Counsel and Corporate Secretary.	— mixed-class rows	90,607 mixed-class rows	$277,803	—	15 Dec 2025	3/4/5
STATE STREET CORP	13F	Company	0.07%	18,617	$221,356	—	30 Sep 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.07%	17,998	$213,996	—	30 Sep 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.06%	17,698	$210,429	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.06%	16,816	$199,942	—	30 Sep 2025	13F

Institutional Holders of CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share (CBIO) as of Q4 2025

As of 31 Dec 2025, CRESCENT BIOPHARMA, INC. - Ordinary Shares, $0.001 par value per share (CBIO) was held by 54 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 23,741,798 shares. The largest 10 holders included FMR LLC, BVF INC/IL, Fairmount Funds Management LLC, VR ADVISER, LLC, FCPM III SERVICES B.V., Vestal Point Capital, LP, Opaleye Management Inc., TANG CAPITAL MANAGEMENT LLC, ADAR1 Capital Management, LLC, and Logos Global Management LP. This page lists 54 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.